A tiny device from healthcare group Johnson & Johnson (JNJ) could help heart attack survivors live longer. That’s the result of its 10-year DanGer Shock trial that has just been released.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The pharmaceutical and medical tech company said it found that its Impella CP heart pump, when used regularly, supports patients with cardiogenic shock — a condition where the heart fails to supply enough blood. The device could reduce the risk of death by 16.3% and extend life by approximately 1.6 years compared to patients who receive standard care, the firm said.
The New Jersey-based company published the findings of the trial in the New England Journal of Medicine. The multinational also said it simultaneously presented the findings of the trial at the European Society of Cardiology Congress.
Pharmaceuticals Plan U.S. Sales Boost
The results come as the pharmaceutical giant looks to double down on its production capacity in the U.S. in the face of tariff pressure on the sector by President Donald Trump’s administration. Earlier in March, the company disclosed plans to boost its American investments by pumping more than $55 billion over the next four years into its business in the country.
Other pharmaceutical companies such as AstraZeneca (AZN) and Eli Lilly (LLY) are also making plans to scale up their production in the country. For instance, AstraZeneca in late July noted that it intended to commit $50 billion to research and development as well as manufacturing in the U.S.
The goal of the British-Swedish pharma giant is to hit about half of its $80 billion 2030 sales target in the U.S., which is the company’s largest market. This adds to the $3.5 billion the firm pledged in investment late last year.
Is JNJ a Good Stock to Buy Now?
Turning to Wall Street, Johnson & Johnson’s stock has a Moderate Buy consensus rating on TipRanks. This is based on eight Buys and nine Holds by 17 Wall Street analysts.
The average JNJ price target is $177.93, which is a 0.43% potential rise from the stock’s closing price on Friday in the U.S.
